CTO

DRUG2 trials

Sponsors

Tactical Therapeutics, Inc., Annick Desjardins

Conditions

Malignant Glioma (WHO Grade III or IV)Solid Tumors, Glioblastoma, Recurrent Malignant Gliomas

Phase 1

Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas

Active, not recruitingNCT01107522

Tactical Therapeutics, Inc.Solid Tumors, Glioblastoma, Recurrent Malignant Gliomas

Start: 2010-05-31End: 2026-01-31Target: 100Updated: 2025-09-09

Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma

TerminatedNCT01989052

Annick DesjardinsMalignant Glioma (WHO Grade III or IV)

Start: 2014-05-31End: 2016-02-29Updated: 2016-08-04

Related Papers

Phase IB trial of carboxyamidotriazole orotate (CTO) and radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ) in newly diagnosed glioblastoma (GBM).

Journal of Clinical Oncology2016-05-201 citations

Multicenter Phase IB trial of carboxyamidotriazole orotate (CTO) combined with temozolomide (TMZ) for recurrent glioblastoma (GBM) and other malignant gliomas (MG).

Journal of Clinical Oncology2016-05-20

Phase 1 clinical trial of carboxyamidotriazole orotate (CTO) in combination with lomustine (CCNU) for adult patients with recurrent malignant glioma (MG).

Journal of Clinical Oncology2015-05-20

Phase IB trial of carboxyamidotriazole orotate (CTO) and radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ) in newly diagnosed glioblastoma (GBM).

Journal of Clinical Oncology2015-05-20

AT-48 * A PHASE 1 TRIAL OF CARBOXYAMIDOTRIAZOLE OROTATE (CTO) IN COMBINATION WITH BEVACIZUMAB FOR ADULT PATIENTS WITH RECURRENT MALIGNANT GLIOMA POST-BEVACIZUMAB FAILURE

Neuro-Oncology2014-11-01

Phase IB trial of carboxyamidotriazole orotate (CTO) and temozolomide for recurrent malignant glioma (MG): A novel mechanism for modulation of multiple oncogenic pathways.

Journal of Clinical Oncology2014-05-20

Abstract A233: Pharmacodynamic Transcriptional markers of carboxyamidotriazole orotate (CTO) exposure in anagen hair.

Molecular Cancer Therapeutics2013-11-011 citations